Results 201 to 210 of about 15,170 (273)

Immunotherapeutic Approaches to Head and Neck Squamous Cell Carcinoma: Current Clinical Practice and Future Directions

Head &Neck, EarlyView.
ABSTRACT Background Head and neck squamous cell carcinoma (HNSCC) is frequently diagnosed at advanced stages and has historically been associated with poor outcomes. Immune checkpoint inhibition has transformed the therapeutic landscape, offering durable responses in recurrent, metastatic, and locally advanced disease.
Carol R. Bradford, Sreeram M. P., Karthik N. Rao, Orlando Guntinas‐Lichius, Nabil Saba, Alfio Ferlito   +5 more
wiley   +1 more source

Management of toxicities from antibody - drug conjugates in breast cancer. [PDF]

Front Oncol
Gogia A.
europepmc   +1 more source

MET Expression in Upper Gastrointestinal Adenocarcinoma: Prevalence, Prognostic Impact, and Implications for Anti‐MET Antibody‐Drug Conjugate Therapy

International Journal of Cancer, EarlyView.
ABSTRACT MET is an actionable receptor tyrosine kinase, and MET‐directed antibody–drug conjugates (ADCs) have recently entered clinical practice with FDA approval in non‐small cell lung cancer and are now being evaluated across gastrointestinal malignancies, with patient selection based on MET immunohistochemistry (IHC) 3+ membranous staining at ...
Tillmann Bedau, Thomas Zander, Hans Anton Schlößer, Hakan Alakus, Onur Mustafov, Reinhard Büttner, Christiane Bruns, Alexander Quaas   +7 more
wiley   +1 more source

Antibody-Drug Conjugates in Oncology: Principles, Clinical Development, and Future Directions. [PDF]

MedComm (2020)
Cheng B, Gong L, Wang Z, Peng P, Xu K, Huang H, Wu P.   +6 more
europepmc   +1 more source

Engineering Bacteria for Medicine: Delivery, Diagnosis, and Therapy

iMetaMed, EarlyView.
ABSTRACT With rapid advances in synthetic biology and genetic engineering, genetically engineered bacteria (GEB) have emerged as a promising platform for biological therapy, addressing key limitations of conventional drug delivery systems and demonstrating significant clinical potential.
Shiyu Xia, Guiling Fu, Xiaoyue Ding, Wen Yang, Ruijie Bai, Yawei Cai, Jing xuan Zhang, Yanxia Wei, Conghui Han, Yi‐Zhou Gao, Ying Li, Zuobin Zhu   +11 more
wiley   +1 more source

HER2 Heterogeneity in Breast Cancer: Biological Basis, Clinical Implications, and Therapeutic Strategies. [PDF]

Breast Cancer (Dove Med Press)
Shi H, Feng Y, Guo T, Shou W, Li Y.
europepmc   +1 more source

Cysteine Peptidases in Antitumor Immunity: Unraveling Antigen‐Presenting Cell Regulation and Therapeutic Potential

iMetaMed, EarlyView.
This review systematically summarizes the central role of cysteine peptidases in modulating antigen‐presenting cell (APC) function and antitumor immune responses, highlighting their critical significance in overcoming tumor immune evasion. Current research has established that cysteine peptidase subtypes, including cathepsins B, S, L, and X, exert ...
Yimao Wu, Xiaoyan Chen, Zichang Chen, Yalun Liang, Gokhan Zengin, Qian Zhang, Wenlong Sun, Meng‐Yao Li   +7 more
wiley   +1 more source

Antibody-drug conjugates for primary brain tumors. [PDF]

Front Oncol
Gonzalez Castro LN, Santagata S.
europepmc   +1 more source

Strategies and mechanisms of precision genome engineering: From gene editing to genome writing

iMetaOmics, EarlyView.
In this review, we examined the progression of genome manipulation from stochastic nuclease‐mediated cutting toward precise editing and programmable genome writing. We discussed tools like multi‐kilobase RNA‐guided integrators and Artificial Intelligence (AI)‐designed effectors and showed how these advances enable researchers to treat genomes as ...
Kerui Huang, Jianhong Tian, Wenyan Zhao, Siqin Zhang, Lixuan Xiang, Meiqing Yang, Lu Liu, Yazhou Huang, Ningyun Zhang, Lei Sun, Peng Xie, Nanyu Kuang, Hong Zhou, Chengfeng Qiu, Jun Yan, Xiaocheng Jiang, Qiang Tu, Yun Wang, Haoliang Hu, Youming Zhang   +19 more
wiley   +1 more source

Next-generation antibody-drug conjugates in drug-resistant solid tumors: promise, toxicity, and the emerging challenge of acquired resistance. [PDF]

Ann Med Surg (Lond)
Khan SA, Ali T, Khan A, Hameed A, Tahir A, Qamar MA.   +5 more
europepmc   +1 more source